Business Wire

SMOORE

Share
SMOORE Outlines Its Mission of “atomization making life better” at GTNF 2021

SMOORE, a global leader in offering vaping technology solutions, today has made its mark at The Global Tobacco & Nicotine Forum (GTNF) 2021. Senior Vice President of SMOORE and President of FEELM, the flagship atomization tech brand belonging to SMOORE, Frank Han makes the keynote speech to outline SMOORE’s mission of “atomization making life better.”

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210923005511/en/

The Global Tobacco & Nicotine Forum (GTNF) is the world’s leading annual forum discussing the future of the tobacco and nicotine industries. The annual industry conference brings together key stakeholders from around the world, including global tobacco companies, vaping brands, scientists, public health experts, NGOs and policymakers.

In his speech, Frank Han calls upon all stakeholders of the industry to join the mission of “atomization making life better”, promoting the evolution of atomization ecosystem . He asserts that policymakers and NGOs should take the lead in institutional innovations to promote the healthier industry development and more balanced regulations, embracing vaping as a strategy to improve public health while safeguarding against youth vaping. Global media could also involve more people in the unbiased public dialogue on vaping.

Moreover, industry leaders should work together to build up more comprehensive industry standards. As one of the key industry standard setters, SMOORE has developed its vapor and material safety standards, which involve over 300 physical and chemical tests. These standards have also covered all of PMTA tests and the safety evaluation of over 50 atomization materials, thereby guaranteeing industry-leading product quality.

In terms of product innovation , Frank Han indicates that the underlying technology of vaping—atomization, has showed promising prospects in other fields, such as healthcare. With one of its R&D focus on the atomization application in healthcare, SMOORE has made significant progress on the research of atomized medication in the past three years.

“In the near future, more and more people will inhale medicines or vaccines with atomization devices. It could help the world pull through the pandemic,” said Frank Han.

According to Frank Han, SMOORE’s innovations are based on its insights into global consumers’ requirements and the commitment to improving user experience, which is the company’s first principle of product development. Based on the principle, SMOORE launched the world’s first Taste Evaluation Model in 2020, covering 4 dimensions and 51 indexes, so as to establish a scientific system to evaluate vaping tastes.

Moreover, Frank Han points out that scientific innovation is the driving force of the industry’s evolution. Industry pioneers are constantly committed to the cross-disciplinary fundamental research of “atomization science”, to explore the mechanism of atomization.

As the world’s leading atomization tech platform, SMOORE has recruited R&D experts from different backgrounds and built up 7 global research centers around the world. In addition to in-house R&D resources, SMOORE has partnered with top universities to leverage the latest scientific discoveries and transform them into cutting–edge applied technologies.

The industry is also embracing intelligent manufacturing to improve resource efficiency. For example, SMOORE introduced the first fully automated pod production line in the world. Now, a single line of SMOORE can produce 7,200 standard vaporizers per hour.

In partnership with clients, SMOORE has also adopted sustainable practices in all stages of product development, especially manufacturing, so as to fulfill its commitment to reducing carbon footprint.

“Innovation and sustainability are the ideas to which the whole industry has been adhering, since the advent of vaping. The two ideas share a common goal, that is ‘atomization making life better’, which echoes SMOORE’s corporate mission,” said Frank Han.

Committed to the mission of “Atomization making life better”, SMOORE will continue to discover more diversified atomization methods and more advanced technology roadmap while jointly promoting a more inclusive dialogue mechanism along with partners from different sectors.

About SMOORE

SMOORE is a global leader in offering vaping technology solutions, including manufacturing vaping devices, and vaping components, with advanced R&D technology, strong manufacturing capacity, wide-spectrum product portfolio and diverse customer base. The Company is the world's largest vaping device manufacturer in terms of revenue, accounting for 18.9% of the total global market share.

About FEELM

FEELM is a high-end atomization technology brand belonging to SMOORE. Focusing on the research of cutting-edge atomization technology, FEELM also specializes in the development and manufacturing of high quality atomization devices driven by FEELM ceramic coil. “FEELM inside” symbol is on the closed system pods of a number of global leading tobacco companies and vaping companies around the world. The accumulated sales volume of FEELM has surpassed 3 billion pieces per year.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release

At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,

Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release

Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP

Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release

Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through

Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse

Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye